About PharmAthene
PharmAthene is a publicly listed company based in Annapolis (United States) founded in 2001. Developing anthrax vaccine designed to protect against inhalational anthrax. PharmAthene has raised $50 million across 3 funding rounds. The company has 15 employees. PharmAthene has completed 1 acquisition, including Altimmune. Its chief executive, as recorded, is Vipin K Garg. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is PHARMATHENE INC. Its competitors include Insmed, Affinivax and Aridis Pharma; 2 of its 3 listed competitors have raised funding.
Company details
PharmAthene is a biopharma company that focuses on defensive countermeasures against biological and chemical warfare. The company is in beginning animal studies on its next generation anthrax vaccine based on its proprietary vaccine development platform, and hopes to file for FDA approvals for human trials in 2017. Additionally, the company has also entered into an agreement with ImmunoVaccine Technologies for the exclusive use of its DepoVaxTM vaccine platform to develop an anthrax vaccine utilizing its Recombinant Protective Antigen system.
- Headquarters Annapolis, United States
- Employees 15
- Stage Public
- SectorsHealthcare
- Website pharmathene.com
- Social LinkedIn X
- Legal Name Pharmathene Inc.
- Total Equity Funding$50M (USD)
in 3 rounds
- Latest Funding Round$9.9M (USD), Post-IPO
Nov 2010
- Employee Count15
- Investments & Acquisitions
Funding Insights of PharmAthene
PharmAthene has successfully raised a total of $50M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9.9 million completed in November 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50M
- Total Rounds 3
- Last Round Post-IPO — $9.9M
- First Round $50M
(Oct 2004)
All 3 funding rounds of PharmAthene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2010 | $9.9M | Post-IPO | – | – | – |
| Aug 2009 | $19.3M | Post-IPO | – | – | – |
| Oct 2004 | $50M | Series B | – | – | – |
People of PharmAthene
1 people are tracked at PharmAthene (1 in leadership); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Vipin K Garg | CEO | Leadership |
Complete people profiles for PharmAthene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PharmAthene
PharmAthene has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Altimmune.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Vaccines for infectious diseases and solid tumors are developed. | altimmune.com | Gaithersburg, United States | 1997 | Jan 2017 | •••• |
Complete acquisition details for PharmAthene
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of PharmAthene
5 dated milestones of PharmAthene across 16 years, from founding to its latest funding, stage changes and deals.
- Founded PharmAthene is founded.
- Funding First funding round of $50.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $9.9M.
- Acquisition Acquires Altimmune.
Competitors of PharmAthene
PharmAthene has 3 listed competitors in our database, 2 of them funded. They include Insmed, Affinivax and Aridis Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | 912 | Developer of small molecule inhibitors for rare lung diseases | ||
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| aridispharma.com | 2005 | San Jose, United States | $42.11M | 34 | Provider of human monoclonal antibodies against infectious diseases |
Detailed competitors of PharmAthene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PharmAthene
Websites that share an audience with PharmAthene (pharmathene.com).
Websites whose visitors overlap most with PharmAthene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| rcmd.com | 100% | #3,561,768 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as PharmAthene (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pharmathene
Complete news archive for PharmAthene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PharmAthene
PharmAthene was founded in 2001 and raised its 1st funding round 3 years after it was founded.
PharmAthene is headquartered in Annapolis, United States. It is registered at Annapolis, Maryland, United States.
Vipin K Garg is the CEO of PharmAthene, as recorded in our data.
PharmAthene is a funded company, having raised a total of $50M across 3 funding rounds to date. The company's 1st funding round was a Series B of $50M, raised on Oct 2004.
PharmAthene has 15 employees.
PharmAthene is a biopharma company that focuses on defensive countermeasures against biological and chemical warfare. The company is in beginning animal studies on its next generation anthrax vaccine based on its proprietary vaccine development platform, and hopes to file for FDA approvals for human trials in 2017. Additionally, the company has also entered into an agreement with ImmunoVaccine Technologies for the exclusive use of its DepoVaxTM vaccine platform to develop an anthrax vaccine utilizing its Recombinant Protective Antigen system.
PharmAthene's top competitors include Aridis Pharma, Insmed and Affinivax.
PharmAthene has made 1 acquisition, including Altimmune.
PharmAthene operates through Pharmathene Inc..